Fujifilm Breaks Ground for Facility Expansion; Sterling Acquires ADC BioBy
The latest from CDMOs, CMOs, and suppliers featuring Fujifilm Diosynth Biotechnologies, Sterling Pharma Solutions, ADC Bio, Bora Pharmaceuticals, Crystec, and Cryoport.
Fujifilm Diosynth Breaks Ground for Microbial Facility Expansion
Fujifilm Diosynth Biotechnologies, a biologics CDMO and a subsidiary of Fujifilm Corporation, held a virtual ground-breaking ceremony to mark the start of a microbial facility expansion at its site in Teesside, UK. The company is investing JPY 9 billion ($82 million) in the expansion.
The expansion will triple the facilities’ current production capacity with a new production line equipped with 2 X 2.000-L fermenters and a modular purification suite. The utilities at the facility are being upgraded to accommodate for high-volume production using a combination of traditional and the company’s proprietary SymphonX technologies. The facility expansion will be operational in early 2022.
Source: Fujifilm Diosynth Biotechnologies
Sterling Pharma Solutions Acquires ADC Bio
Sterling Pharma Solutions, a Dudley, UK-based CDMO of small-molecule active pharmaceutical ingredients (APIs) and intermediates, has acquired ADC Biotechnology (ADC Bio), a Chester, UK-based CDMO of antibody drug conjugates (ADCs).
This acquisition follows an announcement by Sterling in December (December 2020) of a strategic investment into the ADC Bio business with the aim for acquisition in 2021.
ADC Bio’s facility in Deeside, North Wales, UK will rebrand to become part of Sterling’s international network. Together, the teams will establish a center of excellence for bioconjugation and ADC development and manufacturing. A multi-million dollar investment will support the growth of Sterling’s ADC capabilities, including growing and developing the existing bioconjugation technical services team and expanding the analytical services team, particularly in the cGMP area. Additionally, the team will develop and establish cGMP bioconjugation/ADC manufacturing at Deeside in 2022.
The announcement follows Sterling’s acquisition of a small-molecule API manufacturing facility in Germantown, Wisconsin from Alcami in September (September 2020). Sterling now employs over 750 people across the UK and the US.
Source: Sterling Pharma Solutions
Formulation Development/Drug-Product Manufacturing
Crystec Launches New Subsidiary, R&D Center in China
Crystec, a Bradford, UK-based company providing pharmaceutical crystal and particle-engineering services, has opened a new subsidiary, Nantong Crystec Pharmaceutical R&D Co., and research facility in Haimen City, Jiangsu, China.
The new Haimen facility will support Crystec’s ongoing development strategy in China, working alongside Crystec’s existing China subsidiary, Tianjin Crystec Pharmaceutical Technology, and its UK headquarters in Bradford to expand and enhance product development services offered across the region and globally.
Crystec’s new R&D center has been established following an invitation to participate in the Yangtze Delta Advanced Drug Development platform jointly funded by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and the Haimen government.
The platform, which has received £550 million ($765 million) equivalent in investment, is focused on advanced pharmaceutical excipients and drug-delivery technologies.
Bora Pharmaceuticals Adds Roller Compaction Capabilities
Bora Pharmaceutical Laboratories, a division of Bora Pharmaceuticals, a CDMO of non-sterile oral solid dosage forms, has added roller compaction technology to its solid-dose capability offerings at its contract manufacturing and packaging facility in Zhunan, Taiwan.
The Zhunan facility is one of Bora’s three CMO sites and manufactures products for the North American and European markets. The company also recently completed the acquisition of GSK’s Mississauga, Ontario, Canada facility. The site represents Bora Pharmaceuticals’ first manufacturing facility in North America and will become home to its headquarters in the region.
Source: Bora Pharmaceuticals
Cryoport Acquires Australian Temperature-Controlled Logistics Provider
Cryoport, a Brentwood, Tennessee-headquartered provider of cold-chain logistics services for temperature-sensitive life-sciences materials, has acquired Critical Transport Solutions Australia (CTSA), a Sydney, Australia-based company providing healthcare logistics management services, for approximately $5 million.
CTSA will be a part of Cryoport’s CRYOPDP business unit and will continue to be run by the current management team. The CTSA acquisition follows the opening of Cryoport Systems and CRYOPDP’s first jointly operated global logistics center in Osaka, Japan in the fourth quarter of 2020 and forms part of the company’s ongoing expansion strategy in the Asia-Pacific region.